Current and Future Medications for Obesity Treatment
Authors:
- 4 November 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (17) , 1551
Abstract
This JAMA Insights article explores a variety of current and emerging nutrient-stimulated, hormone-based medications for the treatment of individuals with obesity.Keywords
This publication has 10 references indexed in Scilit:
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight managementNature Metabolism, 2024
- Transforming obesity: The advancement of multi-receptor drugsCell, 2024
- Targeting the incretin system in obesity and type 2 diabetes mellitusNature Reviews Endocrinology, 2024
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trialThe Lancet Diabetes & Endocrinology, 2024
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityNew England Journal of Medicine, 2023
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialNew England Journal of Medicine, 2023
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- GLP-1 physiology informs the pharmacotherapy of obesityMolecular Metabolism, 2021
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?Trends in Endocrinology & Metabolism, 2020